Translating A New Discovery Into A Novel Cancer Therapy With Grid Therapeutics' Ned Patz, M.D.

Podcast: Business Of Biotech · Ben Comer

Opublikowano: 2026-11-02

We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, Edward (Ned) Patz, M.D., Cofounder and CEO at Grid Therapeutics, explains how a Duke University lab discovery turned into Grid Therapeutics and two clinical-stage cancer immunotherapy programs. Ned talks about discovering the human-derived antibody treatment GT103 and novel Compliment Factor H (CFH) target, the messy realities of funding a new therapeutic approach in cancer, and the leadership lessons that come with running a scrappy virtual biotech. Access this and hundreds of episodes of the <b...